Tag: Heart / Stroke-Related: High Cholesterol
FDA Panel Recommends Approval of Second PCSK9 Inhibitor
Evolocumab (Repatha) for use in patients at very high risk for high cholesterol
FDA Panel Recommends Approval for PCSK9 Inhibitor
Could be used by patients who don't respond to statins
Statins, Fibrates Linked to 30% Lower Stroke Risk in Elderly
But no association between statins and lower risk of coronary heart disease in this group
CDC: Triglyceride Levels Falling for Americans
But many people still at risk
Statins Don’t Reduce Psoriasis Risk
Findings among patients with high, long-term adherence to statins
PCSK9 Inhibitors Cut LDL Cholesterol, CVD Risk
If approved, medications could be used by patients who don't respond to statins
Hydroxychloroquine May Reduce Hyperlipidemia Risk in Early RA
Reduced risk of hyperlipidemia with hydroxychloroquine versus other DMARDs
Visit-to-Visit LDL-C Variability Predicts Cardiac Event Risk
Variability predicts increased risk in patients with coronary artery disease, independent of LDL-C levels
In-Clinic Health Coaching Improves Cardiometabolic Health
Participants receiving health coaching by medical assistants have improved hemoglobin A1c, LDL
ACC: PCSK9 Inhibitors Reduce LDL Cholesterol in Long Term
Two studies show reductions in LDL cholesterol with evolocumab and alirocumab
